Quick Links

Local or global—RAPS has you covered with offices in Washington, DC, Shanghai and Singapore. There are RAPS chapters in Canada, Israel, Switzerland, Taiwan and throughout the United States, and local networks in Australia, Belgium, Brazil, Germany, India, Mexico, The Netherlands, Poland and Singapore.

Quick Links

It’s well-known that the National Institutes of Health (NIH) offers billions of dollars in grants to US academic research facilities. What’s less well-known is that each year, hundreds of new inventions are produced in the laboratories of NIH, the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA), and these inventions are licensed out to private companies in the US and internationally for further research and development, with the hopes of bringing new products to market.

RAPS’ members-only online community, Regulatory Exchange or “RegEx” as it is often called, was recently named one of three “Most Successful Community” award winners of 2016 by Higher Logic. RegEx is built on the Higher Logic platform.

Blumberg started at FDA in 1970 in the Office of the Chief Counsel, and has served as Deputy Chief Counsel since 1991, according to a profile of him maintained by the Federalist Society, a prominent Washington legal society.

Blumberg's position afforded wide oversight over FDA's enforcement activities and litigation against the agency.

In a statement provided to Regulatory Focus on 7 March 2013, Liz Dickinson, Chief Counsel at FDA, said Blumberg would be remembered not only for his contributions to FDA and the public, but for his character as well.

"Rick's dedication to the agency over a 42-year career, and to the effective use of the law to protect the public, was widely recognized," said Dickinson. "Fearless, kind-hearted and brilliant, he nurtured the careers of dozens of food and drug lawyers who carry on his legacy in the government and beyond."

Most Viewed News Articles

Lingering for more than two years, the revamped 21st Century Cures bill, unveiled in late November, has now been approved by the House and Senate and President Barack Obama has said he will sign it.View More

At the end of Thursday's Forbes healthcare summit in New York, some of the pharmaceutical and biotech industries’ top executives – from Pfizer, Regeneron, Eli Lilly, Gilead and Astellas – sat down and were presented with a simple question: Why don’t people like you? View More

After nearly 25 years of service at the US Food and Drug Administration (FDA), John Jenkins, M.D., Director of the Office of New Drugs (OND), will retire from the federal government on 6 January 2017. View More